No-Reflow Risk in Diabetic STEMI Patients After PPCI

A retrospective cohort of 524 patients with type 2 diabetes mellitus (T2DM) and ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PPCI). It was used to develop a predictive model for the no-reflow phenomenon, which occurred in 8.97% of patients, based on the triglyceride-glucose (TyG) index and neutrophil-to-lymphocyte ratio (NLR). The data was authored by Jingyan Yang.

Use Cases

• Train a logistic regression model to predict no-reflow incidence using the TyG index and NLR as independent predictors.
• Analyze the relationship between patient risk groups, defined by TyG and NLR cut-offs, and the incidence of no-reflow.
• Validate the combined predictive performance (AUC) of the TyG + NLR model against baseline clinical factors.
• Stratify patients into four risk groups based on the optimal cut-offs for NLR (2.831) and TyG (9.347) to assess clinical outcomes.

Strengths

• Contains data from 524 patients, a substantial cohort for a clinical study.
• Focuses on a high-risk population (T2DM and STEMI patients) with a defined outcome (no-reflow incidence of 8.97%).
• Includes key predictive biomarkers (TyG index and NLR) with established adjusted odds ratios (aOR 2.98 and 1.23).
• Model performance is quantified with a reported AUC of 0.785 for the combined predictor.

Limitations

• The dataset is relatively small (465.1 KB), indicating limited scope and potentially few variables beyond those described.
• As a retrospective cohort study, it may be subject to selection bias and unmeasured confounding factors.
• The specific columns and sample data are unavailable, limiting detailed understanding of the data structure.

Provenance

Source

figshare, authored by Jingyan Yang.

Collection Method

Retrospective cohort analysis of patients with T2DM and STEMI undergoing PPCI.

Freshness

Last updated on 2026-03-20.